Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 6/20 | 0.45 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.45 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.45 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.45 |
| ▸ | FNTA | P49354 | 2/20 | 0.41 |
| ▸ | FNTB | P49356 | 2/20 | 0.41 |
| ▸ | PGGT1B | P53609 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | NOS2 | P35228 | 1/20 | 0.40 |
| ▸ | EGFR | P00533 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | CTSL | P07711 | 4/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13606496 | 0.83 | CCNE2 (0.41) | PDE5AMEN1KMT2AEGFRPOLB | |
| SCHEMBL13606457 | 0.81 | PDE5A (0.45) | PDE5AMEN1KMT2AEGFRPOLB | |
| SCHEMBL4495080 | 0.80 | PDE5A (0.44) | PDE5AMEN1KMT2AEGFRPOLB | |
| SCHEMBL4498229 | 0.80 | PDE5A (0.44) | PDE5AMEN1KMT2AEGFRPOLB | |
| SCHEMBL4497191 | 0.78 | PDE5A (0.45) | PDE5AMEN1KMT2AEGFRPOLB | |
| SCHEMBL14543523 | 0.77 | CHEK1 (0.41) | PDE3BPDE3A | |
| SCHEMBL13606493 | 0.76 | CTSL (0.44) | PDE5AMEN1KMT2AEGFRPOLB | |
| SCHEMBL5775066 | 0.76 | HTT (0.40) | PDE5AMEN1KMT2AEGFRPOLB | |
| SCHEMBL4503764 | 0.73 | NPC1 (0.40) | PDE5AMEN1KMT2AEGFRPOLB | |
| SCHEMBL4503766 | 0.73 | PDE5A (0.39) | PDE5AMEN1KMT2AEGFRPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7635695-B2 | Antiinflammation agents | AMGEN INC. (US) | 2009-12-22 | — | — | US | disclosed |
| US-7635695-B2 | Antiinflammation agents | AMGEN INC. (US) | 2009-12-22 | — | — | US | disclosed |
| US-20070155777-A1 | Antiinflammation agents | AMGEN, INC. | 2007-07-05 | — | — | US | disclosed |
| US-20070155777-A1 | Antiinflammation agents | AMGEN, INC. | 2007-07-05 | — | — | US | disclosed |
| US-7199119-B2 | Antiinflammation agents | AMGEN INC. (US) | 2007-04-03 | — | — | US | disclosed |
| US-7199119-B2 | Antiinflammation agents | AMGEN INC. (US) | 2007-04-03 | — | — | US | disclosed |
| US-20040097485-A1 | Antiinflammation agents | TULARIK INC. | 2004-05-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070155777-A1 | Antiinflammation agents | TNF, NFATC1, NFKBIA | PDE5A 4558/4885TBXAS1 740/4885PDE3B 4031/4885 |
| US-20040097485-A1 | Antiinflammation agents | TNF, NFATC1, NFKBIA | PDE5A 4558/4885TBXAS1 740/4885PDE3B 4031/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.